Share Price and Basic Stock Data
Last Updated: November 28, 2025, 10:55 am
| PEG Ratio | 4.24 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
DMCC Speciality Chemicals Ltd operates in the specialty chemicals sector, reporting a market capitalization of ₹663 Cr and a share price of ₹266. The company’s sales have shown a fluctuating trend, with revenue recorded at ₹387 Cr for FY 2023, down from ₹431 Cr in FY 2025. However, the trailing twelve months (TTM) figure stands at ₹496 Cr, indicating a potential recovery. Quarterly sales data reveals a peak in March 2025, where sales reached ₹125.19 Cr, while the lowest was noted in December 2022 at ₹71.91 Cr. The operating profit margin (OPM) stood at 13.29%, consistent with the company’s average over recent quarters, suggesting a stable operational efficiency despite revenue fluctuations. The company’s ability to generate sales from operations per share rose to ₹172.93 for FY 2025, reflecting an increasing revenue generation capability. Overall, the company demonstrates resilience in its revenue generation, albeit with some volatility.
Profitability and Efficiency Metrics
The profitability metrics for DMCC Speciality Chemicals Ltd indicate a mixed performance. The net profit for FY 2023 was recorded at ₹7 Cr, which is a significant decline from ₹22 Cr in FY 2025. The earnings per share (EPS) also saw a drop, standing at ₹2.78 for FY 2023, compared to ₹8.63 in FY 2025. Despite these declines, the operating profit remained relatively stable, with an OPM of 13.29% as of the latest quarter, which is a strong indicator of operational efficiency. The company’s return on equity (ROE) stood at 9.97%, while return on capital employed (ROCE) was at 14.1%, both of which are reasonable when benchmarked against industry averages. The cash conversion cycle (CCC) was recorded at 37 days, indicating efficient management of working capital, although it is slightly longer than the typical sector range. Overall, while profitability has faced challenges, efficiency metrics suggest a well-managed operational framework.
Balance Sheet Strength and Financial Ratios
DMCC Speciality Chemicals Ltd exhibits a balanced financial structure, with no reported borrowings, reflecting a debt-free position that enhances its financial stability. The interest coverage ratio (ICR) stood at 5.56x, indicating that the company comfortably meets its interest obligations, which is a positive sign for creditors and investors alike. The price-to-book value ratio (P/BV) is noted at 3.29x, suggesting that the stock is valued at a premium compared to its book value. The current ratio of 1.23x and quick ratio of 0.84x indicate a reasonable liquidity position, although the quick ratio suggests some reliance on inventory for liquidity. The company’s return on assets (ROA) stood at 5.66%, which is moderate compared to industry standards. The balance sheet reflects a strong position with no long-term debt, providing a solid foundation for future growth and investments.
Shareholding Pattern and Investor Confidence
DMCC Speciality Chemicals Ltd’s shareholding pattern reveals a stable promoter holding of 53.84%, which has remained unchanged across reporting periods, indicating strong control by the founding members. The foreign institutional investors (FIIs) hold a mere 0.39%, suggesting limited foreign interest, while domestic institutional investors (DIIs) account for 1.28%, reflecting cautious investment sentiment. The public shareholding stands at 44.49%, with the total number of shareholders reported at 22,015. This distribution suggests a diversified ownership structure, although the low institutional stake may indicate a lack of confidence among larger investors. Over time, the number of shareholders has fluctuated, with a peak of 22,322 in June 2023 and a decline to 20,466 by March 2025, reflecting some volatility in retail interest. Overall, the stable promoter holding is a positive sign, but the low institutional participation could be a concern for long-term growth prospects.
Outlook, Risks, and Final Insight
The outlook for DMCC Speciality Chemicals Ltd appears cautiously optimistic, bolstered by its strong operational metrics and zero debt status. However, the company faces risks, including declining profitability trends, as evidenced by the drop in net profit and EPS in recent years. Moreover, the fluctuation in quarterly sales suggests vulnerability to market conditions and demand variability. The low institutional interest may also pose a risk, potentially affecting stock liquidity and investor confidence. On a positive note, the company’s efficiency in managing working capital and operational expenses presents a foundation for recovery. Should the company manage to stabilize its revenue streams and improve profitability, it could attract more institutional investment. Conversely, failure to address the profitability issues may lead to further declines in investor sentiment. Ultimately, DMCC Speciality Chemicals Ltd stands at a crossroads, where strategic decisions in the near term will significantly influence its trajectory and market perception.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of DMCC Speciality Chemicals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 422 Cr. | 45.9 | 86.7/42.6 | 26.2 | 20.5 | 0.88 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 34.9 Cr. | 71.0 | 103/56.0 | 16.7 | 89.6 | 1.41 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 47.6 Cr. | 699 | 988/600 | 21.9 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,664 Cr. | 80.8 | 111/78.0 | 24.2 | 22.0 | 0.61 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 646 Cr. | 259 | 453/241 | 23.2 | 93.8 | 0.96 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,826.36 Cr | 735.46 | 63.36 | 183.02 | 0.43% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 113.39 | 104.71 | 71.91 | 96.50 | 85.57 | 76.52 | 80.53 | 83.95 | 85.32 | 102.70 | 118.03 | 125.19 | 127.02 |
| Expenses | 98.49 | 101.11 | 70.83 | 80.21 | 74.60 | 66.99 | 73.41 | 76.55 | 76.47 | 87.40 | 100.29 | 110.07 | 110.14 |
| Operating Profit | 14.90 | 3.60 | 1.08 | 16.29 | 10.97 | 9.53 | 7.12 | 7.40 | 8.85 | 15.30 | 17.74 | 15.12 | 16.88 |
| OPM % | 13.14% | 3.44% | 1.50% | 16.88% | 12.82% | 12.45% | 8.84% | 8.81% | 10.37% | 14.90% | 15.03% | 12.08% | 13.29% |
| Other Income | 0.72 | 0.40 | 0.91 | 0.77 | 0.88 | 0.81 | 0.67 | 9.29 | 0.21 | 0.31 | 0.39 | 0.44 | 0.37 |
| Interest | 2.29 | 1.84 | 3.16 | 3.29 | 3.47 | 2.88 | 3.56 | 3.85 | 3.01 | 2.77 | 2.53 | 2.19 | 2.03 |
| Depreciation | 3.32 | 4.92 | 4.80 | 4.54 | 3.55 | 3.90 | 3.91 | 4.33 | 4.16 | 4.25 | 4.25 | 4.03 | 4.19 |
| Profit before tax | 10.01 | -2.76 | -5.97 | 9.23 | 4.83 | 3.56 | 0.32 | 8.51 | 1.89 | 8.59 | 11.35 | 9.34 | 11.03 |
| Tax % | 37.96% | 0.00% | -45.23% | 27.63% | 34.99% | 33.71% | 6.25% | 32.20% | 26.46% | 32.36% | 30.57% | 30.73% | 29.74% |
| Net Profit | 6.22 | -2.77 | -3.28 | 6.68 | 3.14 | 2.36 | 0.29 | 5.78 | 1.39 | 5.80 | 7.88 | 6.47 | 7.75 |
| EPS in Rs | 2.49 | -1.11 | -1.32 | 2.68 | 1.26 | 0.95 | 0.12 | 2.32 | 0.56 | 2.33 | 3.16 | 2.59 | 3.11 |
Last Updated: August 19, 2025, 7:55 pm
Below is a detailed analysis of the quarterly data for DMCC Speciality Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 127.02 Cr.. The value appears strong and on an upward trend. It has increased from 125.19 Cr. (Mar 2025) to 127.02 Cr., marking an increase of 1.83 Cr..
- For Expenses, as of Jun 2025, the value is 110.14 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 110.07 Cr. (Mar 2025) to 110.14 Cr., marking an increase of 0.07 Cr..
- For Operating Profit, as of Jun 2025, the value is 16.88 Cr.. The value appears strong and on an upward trend. It has increased from 15.12 Cr. (Mar 2025) to 16.88 Cr., marking an increase of 1.76 Cr..
- For OPM %, as of Jun 2025, the value is 13.29%. The value appears strong and on an upward trend. It has increased from 12.08% (Mar 2025) to 13.29%, marking an increase of 1.21%.
- For Other Income, as of Jun 2025, the value is 0.37 Cr.. The value appears to be declining and may need further review. It has decreased from 0.44 Cr. (Mar 2025) to 0.37 Cr., marking a decrease of 0.07 Cr..
- For Interest, as of Jun 2025, the value is 2.03 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.19 Cr. (Mar 2025) to 2.03 Cr., marking a decrease of 0.16 Cr..
- For Depreciation, as of Jun 2025, the value is 4.19 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.03 Cr. (Mar 2025) to 4.19 Cr., marking an increase of 0.16 Cr..
- For Profit before tax, as of Jun 2025, the value is 11.03 Cr.. The value appears strong and on an upward trend. It has increased from 9.34 Cr. (Mar 2025) to 11.03 Cr., marking an increase of 1.69 Cr..
- For Tax %, as of Jun 2025, the value is 29.74%. The value appears to be improving (decreasing) as expected. It has decreased from 30.73% (Mar 2025) to 29.74%, marking a decrease of 0.99%.
- For Net Profit, as of Jun 2025, the value is 7.75 Cr.. The value appears strong and on an upward trend. It has increased from 6.47 Cr. (Mar 2025) to 7.75 Cr., marking an increase of 1.28 Cr..
- For EPS in Rs, as of Jun 2025, the value is 3.11. The value appears strong and on an upward trend. It has increased from 2.59 (Mar 2025) to 3.11, marking an increase of 0.52.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:29 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 101 | 120 | 108 | 175 | 178 | 227 | 188 | 200 | 326 | 387 | 328 | 431 | 496 |
| Expenses | 86 | 101 | 91 | 145 | 155 | 174 | 160 | 165 | 286 | 351 | 292 | 374 | 433 |
| Operating Profit | 15 | 20 | 16 | 30 | 23 | 53 | 28 | 36 | 41 | 36 | 36 | 57 | 64 |
| OPM % | 15% | 16% | 15% | 17% | 13% | 24% | 15% | 18% | 12% | 9% | 11% | 13% | 13% |
| Other Income | 6 | -1 | 0 | 1 | 1 | 1 | 6 | 8 | 6 | 3 | 10 | 1 | 2 |
| Interest | 2 | 2 | 1 | 5 | 4 | 3 | 2 | 2 | 5 | 11 | 14 | 10 | 9 |
| Depreciation | 3 | 2 | 2 | 4 | 4 | 5 | 6 | 7 | 8 | 18 | 16 | 17 | 17 |
| Profit before tax | 16 | 14 | 13 | 21 | 16 | 47 | 26 | 34 | 34 | 10 | 17 | 31 | 40 |
| Tax % | 0% | 0% | 9% | 21% | 21% | 2% | -22% | 4% | 37% | 35% | 33% | 31% | |
| Net Profit | 16 | 14 | 12 | 17 | 12 | 46 | 31 | 33 | 21 | 7 | 12 | 22 | 28 |
| EPS in Rs | 7.55 | 6.58 | 5.63 | 7.79 | 4.92 | 18.47 | 12.63 | 13.06 | 8.56 | 2.75 | 4.64 | 8.64 | 11.17 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 10% | 8% | 0% | 15% | 6% | 0% | 22% | 29% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -12.50% | -14.29% | 41.67% | -29.41% | 283.33% | -32.61% | 6.45% | -36.36% | -66.67% | 71.43% | 83.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | -1.79% | 55.95% | -71.08% | 312.75% | -315.94% | 39.06% | -42.82% | -30.30% | 138.10% | 11.90% |
DMCC Speciality Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 18% |
| 3 Years: | 10% |
| TTM: | 45% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -7% |
| 3 Years: | 1% |
| TTM: | 184% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 14% |
| 3 Years: | -8% |
| 1 Year: | 10% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 9% |
| 3 Years: | 5% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 3:16 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 44 | 44 | 45 | 45 | 48 | 48 | 58 | 56 | 49 | 51 | 63 |
| Inventory Days | 52 | 62 | 104 | 60 | 73 | 80 | 113 | 151 | 79 | 78 | 81 | 58 |
| Days Payable | 126 | 76 | 115 | 129 | 114 | 79 | 68 | 116 | 131 | 121 | 119 | 84 |
| Cash Conversion Cycle | -12 | 29 | 33 | -25 | 4 | 49 | 93 | 94 | 3 | 6 | 13 | 37 |
| Working Capital Days | 15 | 1 | -7 | -37 | -6 | 43 | 80 | 32 | -5 | 2 | 5 | 16 |
| ROCE % | 34% | 34% | 24% | 35% | 21% | 43% | 18% | 19% | 16% | 7% | 8% | 14% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 8.63 | 4.65 | 2.78 | 8.56 | 13.06 |
| Diluted EPS (Rs.) | 8.63 | 4.65 | 2.78 | 8.56 | 13.06 |
| Cash EPS (Rs.) | 15.34 | 10.95 | 9.84 | 11.79 | 15.80 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 91.25 | 84.02 | 79.49 | 77.64 | 69.44 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 91.25 | 84.02 | 79.49 | 77.64 | 69.44 |
| Revenue From Operations / Share (Rs.) | 172.93 | 131.50 | 154.26 | 130.83 | 80.25 |
| PBDIT / Share (Rs.) | 23.40 | 18.73 | 15.55 | 18.48 | 17.35 |
| PBIT / Share (Rs.) | 16.70 | 12.43 | 8.49 | 15.25 | 14.61 |
| PBT / Share (Rs.) | 12.48 | 6.92 | 4.25 | 13.69 | 13.65 |
| Net Profit / Share (Rs.) | 8.63 | 4.65 | 2.78 | 8.56 | 13.06 |
| NP After MI And SOA / Share (Rs.) | 8.63 | 4.65 | 2.78 | 8.56 | 13.06 |
| PBDIT Margin (%) | 13.53 | 14.24 | 10.07 | 14.12 | 21.61 |
| PBIT Margin (%) | 9.65 | 9.45 | 5.50 | 11.65 | 18.20 |
| PBT Margin (%) | 7.21 | 5.26 | 2.75 | 10.46 | 17.00 |
| Net Profit Margin (%) | 4.99 | 3.53 | 1.80 | 6.54 | 16.27 |
| NP After MI And SOA Margin (%) | 4.99 | 3.53 | 1.80 | 6.54 | 16.27 |
| Return on Networth / Equity (%) | 9.45 | 5.53 | 3.49 | 11.02 | 18.81 |
| Return on Capital Employeed (%) | 15.38 | 11.47 | 7.88 | 15.10 | 18.68 |
| Return On Assets (%) | 5.66 | 3.07 | 1.72 | 5.56 | 12.35 |
| Long Term Debt / Equity (X) | 0.17 | 0.27 | 0.34 | 0.28 | 0.09 |
| Total Debt / Equity (X) | 0.20 | 0.31 | 0.40 | 0.40 | 0.14 |
| Asset Turnover Ratio (%) | 1.14 | 0.84 | 0.98 | 1.01 | 0.84 |
| Current Ratio (X) | 1.23 | 1.08 | 1.04 | 0.95 | 1.68 |
| Quick Ratio (X) | 0.84 | 0.66 | 0.63 | 0.64 | 1.13 |
| Inventory Turnover Ratio (X) | 9.95 | 4.03 | 5.48 | 5.09 | 2.94 |
| Dividend Payout Ratio (NP) (%) | 11.58 | 0.00 | 35.98 | 5.84 | 11.68 |
| Dividend Payout Ratio (CP) (%) | 6.52 | 0.00 | 10.16 | 4.24 | 9.65 |
| Earning Retention Ratio (%) | 88.42 | 0.00 | 64.02 | 94.16 | 88.32 |
| Cash Earning Retention Ratio (%) | 93.48 | 0.00 | 89.84 | 95.76 | 90.35 |
| Interest Coverage Ratio (X) | 5.56 | 3.40 | 3.67 | 11.84 | 18.03 |
| Interest Coverage Ratio (Post Tax) (X) | 3.05 | 1.84 | 1.66 | 6.48 | 14.57 |
| Enterprise Value (Cr.) | 789.57 | 745.75 | 677.05 | 982.66 | 815.55 |
| EV / Net Operating Revenue (X) | 1.83 | 2.27 | 1.76 | 3.01 | 4.07 |
| EV / EBITDA (X) | 13.53 | 15.96 | 17.46 | 21.32 | 18.85 |
| MarketCap / Net Operating Revenue (X) | 1.74 | 2.09 | 1.56 | 2.78 | 3.96 |
| Retention Ratios (%) | 88.41 | 0.00 | 64.01 | 94.15 | 88.31 |
| Price / BV (X) | 3.29 | 3.27 | 3.02 | 4.69 | 4.58 |
| Price / Net Operating Revenue (X) | 1.74 | 2.09 | 1.56 | 2.78 | 3.96 |
| EarningsYield | 0.02 | 0.01 | 0.01 | 0.02 | 0.04 |
After reviewing the key financial ratios for DMCC Speciality Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.63. This value is within the healthy range. It has increased from 4.65 (Mar 24) to 8.63, marking an increase of 3.98.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.63. This value is within the healthy range. It has increased from 4.65 (Mar 24) to 8.63, marking an increase of 3.98.
- For Cash EPS (Rs.), as of Mar 25, the value is 15.34. This value is within the healthy range. It has increased from 10.95 (Mar 24) to 15.34, marking an increase of 4.39.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 91.25. It has increased from 84.02 (Mar 24) to 91.25, marking an increase of 7.23.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 91.25. It has increased from 84.02 (Mar 24) to 91.25, marking an increase of 7.23.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 172.93. It has increased from 131.50 (Mar 24) to 172.93, marking an increase of 41.43.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 23.40. This value is within the healthy range. It has increased from 18.73 (Mar 24) to 23.40, marking an increase of 4.67.
- For PBIT / Share (Rs.), as of Mar 25, the value is 16.70. This value is within the healthy range. It has increased from 12.43 (Mar 24) to 16.70, marking an increase of 4.27.
- For PBT / Share (Rs.), as of Mar 25, the value is 12.48. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 12.48, marking an increase of 5.56.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 8.63. This value is within the healthy range. It has increased from 4.65 (Mar 24) to 8.63, marking an increase of 3.98.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.63. This value is within the healthy range. It has increased from 4.65 (Mar 24) to 8.63, marking an increase of 3.98.
- For PBDIT Margin (%), as of Mar 25, the value is 13.53. This value is within the healthy range. It has decreased from 14.24 (Mar 24) to 13.53, marking a decrease of 0.71.
- For PBIT Margin (%), as of Mar 25, the value is 9.65. This value is below the healthy minimum of 10. It has increased from 9.45 (Mar 24) to 9.65, marking an increase of 0.20.
- For PBT Margin (%), as of Mar 25, the value is 7.21. This value is below the healthy minimum of 10. It has increased from 5.26 (Mar 24) to 7.21, marking an increase of 1.95.
- For Net Profit Margin (%), as of Mar 25, the value is 4.99. This value is below the healthy minimum of 5. It has increased from 3.53 (Mar 24) to 4.99, marking an increase of 1.46.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.99. This value is below the healthy minimum of 8. It has increased from 3.53 (Mar 24) to 4.99, marking an increase of 1.46.
- For Return on Networth / Equity (%), as of Mar 25, the value is 9.45. This value is below the healthy minimum of 15. It has increased from 5.53 (Mar 24) to 9.45, marking an increase of 3.92.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.38. This value is within the healthy range. It has increased from 11.47 (Mar 24) to 15.38, marking an increase of 3.91.
- For Return On Assets (%), as of Mar 25, the value is 5.66. This value is within the healthy range. It has increased from 3.07 (Mar 24) to 5.66, marking an increase of 2.59.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.17. This value is below the healthy minimum of 0.2. It has decreased from 0.27 (Mar 24) to 0.17, marking a decrease of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.20. This value is within the healthy range. It has decreased from 0.31 (Mar 24) to 0.20, marking a decrease of 0.11.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.14. It has increased from 0.84 (Mar 24) to 1.14, marking an increase of 0.30.
- For Current Ratio (X), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 1.5. It has increased from 1.08 (Mar 24) to 1.23, marking an increase of 0.15.
- For Quick Ratio (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.84, marking an increase of 0.18.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.95. This value exceeds the healthy maximum of 8. It has increased from 4.03 (Mar 24) to 9.95, marking an increase of 5.92.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 11.58. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 24) to 11.58, marking an increase of 11.58.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.52. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 24) to 6.52, marking an increase of 6.52.
- For Earning Retention Ratio (%), as of Mar 25, the value is 88.42. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 88.42, marking an increase of 88.42.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.48. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 93.48, marking an increase of 93.48.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.56. This value is within the healthy range. It has increased from 3.40 (Mar 24) to 5.56, marking an increase of 2.16.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.05. This value is within the healthy range. It has increased from 1.84 (Mar 24) to 3.05, marking an increase of 1.21.
- For Enterprise Value (Cr.), as of Mar 25, the value is 789.57. It has increased from 745.75 (Mar 24) to 789.57, marking an increase of 43.82.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.83. This value is within the healthy range. It has decreased from 2.27 (Mar 24) to 1.83, marking a decrease of 0.44.
- For EV / EBITDA (X), as of Mar 25, the value is 13.53. This value is within the healthy range. It has decreased from 15.96 (Mar 24) to 13.53, marking a decrease of 2.43.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.74. This value is within the healthy range. It has decreased from 2.09 (Mar 24) to 1.74, marking a decrease of 0.35.
- For Retention Ratios (%), as of Mar 25, the value is 88.41. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 88.41, marking an increase of 88.41.
- For Price / BV (X), as of Mar 25, the value is 3.29. This value exceeds the healthy maximum of 3. It has increased from 3.27 (Mar 24) to 3.29, marking an increase of 0.02.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.74. This value is within the healthy range. It has decreased from 2.09 (Mar 24) to 1.74, marking a decrease of 0.35.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in DMCC Speciality Chemicals Ltd:
- Net Profit Margin: 4.99%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.38% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 9.45% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.05
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.84
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 23.2 (Industry average Stock P/E: 63.36)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.2
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.99%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Prospect Chambers, 317/321, Dr. Dadabhoy Naoroji Road, Mumbai Maharashtra 400001 | investors@dmcc.com http://www.dmcc.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Laxmikumar Narottam Goculdas | Chairman |
| Ms. Mitika Laxmikumar Goculdas | Vice Chairperson |
| Mr. Bimal Lalitsingh Goculdas | Managing Director & CEO |
| Mr. Kuldeep Kumar Tiwari | Executive Director - Operations |
| Mr. Mukul Manoharlal Taly | Ind. Non-Executive Director |
| Mr. Sanjeev Vishwanath Joshi | Ind. Non-Executive Director |
| Dr.(Mrs.) Janaki Ashwin Patwardhan | Ind. Non-Executive Director |
| Mr. Haren Devidas Parekh | Ind. Non-Executive Director |